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Abstract: The detection of borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a
challenge to both, veterinary and human laboratories. Between 2015 and 2017, 19 equine S. aureus with
elevated minimal inhibitory concentrations for oxacillin were detected in routine diagnostics. The aim
of this study was to characterize these isolates to identify factors possibly associated with the BORSA
phenotype. All S. aureus were subjected to antimicrobial susceptibility testing and whole genome
sequencing (WGS). A quantifiable β-lactamase activity assay was performed for a representative
subset of 13 isolates. The WGS data analysis of the 19 BORSA isolates identified two different genomic
lineages, sequence type (ST) 1 and ST1660. The core genome multilocus sequence typing (cgMLST)
revealed a close relatedness of all isolates belonging to either ST1 or ST1660. The WGS analysis
identified the resistance genes aadD, dfrG, tet(L), and/or blaZ and aacA-aphD. Phenotypic resistance to
penicillins, aminoglycosides, tetracyclines, fluoroquinolones and sulfamethoxazole/trimethoprim was
observed in the respective isolates. For the penicillin-binding proteins 1–4, amino acid substitutions
were predicted using WGS data. Since neither transglycosylase nor transpeptidase domains were
affected, these alterations might not explain the BORSA phenotype. Moreover, β-lactamase activity
was found to be associated with an inducible blaZ gene. Lineage-specific differences regarding the
expression profiles were noted.
Keywords: borderline oxacillin resistance; BORSA; susceptibility testing; MSSA; whole genome
sequencing; blaZ
Key Contribution: This study characterizes two lineages of S. aureus causing infections in an equine
clinic and analyzes the genetic basis of their borderline oxacillin resistance.
1. Introduction
Staphylococcus aureus can be a harmless commensal residing on the skin and mucosal surfaces
of healthy animals and humans [1], but it can also cause a broad spectrum of diseases, ranging
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from relatively mild skin infections to life-threatening pneumonia, sepsis and endocarditis [2,3].
The infections caused by antimicrobial-resistant staphylococci are a major threat in human and
veterinary medicine, since treatment options are often limited [3–5]. A broad range of different
staphylococcal species has been detected in horses, including S. aureus and Staphylococcus delphini
as coagulase-positive species, but also a variety of coagulase-negative staphylococci [6–10]. Several
studies on equine S. aureus and, in particular, equine methicillin-resistant S. aureus (MRSA) have been
performed in recent years [11–15].
Besides MRSA, also borderline oxacillin-resistantS. aureus (BORSA) gained particular attention [16].
Commonly, BORSA were initially defined by their reduced susceptibility to oxacillin with minimal
inhibitory concentrations (MICs) of 1–2 mg/L, but some BORSA strains can also exhibit oxacillin MICs
of 4–16 mg/L [16]. These isolates lack an additional penicillin-binding protein (PBP), encoded by either
mecA or mecC, which are located on mobile genetic elements, the Staphylococcal Cassette Chromosome
mec (SCCmec) in MRSA [1,16] or mecB carried on a plasmid, as recently described [17].
S. aureus isolates are assigned to clonal complexes (CC) based on their multi locus sequence types
(STs). Since 2005, livestock-associated MRSA (LA-MRSA), in Europe attributed to CC398, became
a public health issue, colonizing animals and humans. In addition, LA-MRSA were described for
human cases of wound infection, deep abscess, cellulitis, necrotizing fasciitis and bacteremia [18,19].
In Europe, CC398 with spa type t011, but also other spa types such as t034 and t6867, is the most
common clonal complex among MRSA in horse clinics [6,11,13,20–27]. However, several studies also
observed a low number of isolates (MRSA and methicillin-susceptible S. aureus (MSSA)) attributed
to CC1 with spa type t127 [6,11,21,25,26]. This clonal complex is known to be also associated with
infections in humans, causing the majority of staphylococcal bacteremia in Denmark [28]. In other
countries, such as England [29], Spain [30], Norway [31], Turkey [32] and Italy [33], CC1 is detected at
lower frequencies. Other studies focusing on equine clinics found isolates with spa types t549 [6,25,26]
and t3034 [21,26], which belong to ST1660. This ST has not been assigned to a clonal complex so far.
Previous studies showed an increase of both, MRSA and BORSA in equine clinics [20,21]. Moreover,
there has been evidence that, once resistant staphylococcal isolates enter a human or veterinary
clinic [11,34,35], the number of nosocomial infections—in particular wound infections [34,35]—increases.
Nosocomial settings provide a selective pressure to bacterial pathogens since antimicrobial agents
and also biocides are widely used [36,37]. While horse clinics have been identified as “hot spots” for
pathogens accumulating antibiotic resistance in the recent past, little is known about frequency and
dimension of biocide resistance. Consequently, more research is needed in this particular field and
biocide susceptibility of field isolates should be monitored. However, studies determining MICs for
biocides often lack an approved method and are therefore difficult to compare [37].
The aim of this study was to thoroughly characterize S. aureus of equine origin with elevated
oxacillin MICs ranging from 0.5 mg/L to≥4 mg/L via VITEK2 while lacking known methicillin resistance
genes, such as mecA and mecC.
2. Results
2.1. Molecular Typing of Equine BORSA Isolates
The investigation of the whole genome sequences (WGSs) of the 19 isolates revealed two multi
locus sequence (MLS) types, ST1 (n = 3, allelic profile: 1-1-1-1-1-1-1) and ST1660 (n = 16, allelic
profile: 6-79-6-47-89-70-61). All ST1 isolates had spa type t127 (repeats: 07-23-21-16-34-33-13), whereas
the ST1660 isolates displayed three different spa types, namely t549 (n = 1, IMT41899), t2484 (n = 1,
IMT39637) and t3043 (n = 14). A comparison of these spa types revealed only differences in the number
of the terminal repeats (Figure 1):
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Figure 1. Comparison of the spa types, obtained for the ST1660 isolates.
2.2. Phylogenetic Analysis
The core genome ultilocus sequence typing (cgMLST) analysis revealed 14 different allelic
profiles and two different clusters for the 19 BORSA isolates (Figure 2). Cluster 1 represented the ST1
sequences and co sist of two closely relat allelic profiles differing only in one target gene. Cluster
2 included the ST1660 isolates assigned to 12 distinct, but also closely related allelic profiles differing in
0 to 7 target genes only. The phylogenetic relationship of the two clusters was considerably distant,
mirrored by the differences in 1697 of 1744 alleles included in the comparison.
Toxins 2019, 10, x FOR PEER REVIEW  3 of 21 
 
 
 
Figure 1. Comparison of the spa types, obtained for the ST1660 isolates. 
2.2. Phylogenetic Analysis 
The core genome multilocus sequence typing (cgMLST) analysis revealed 14 different allelic 
profiles and two different clusters for the 19 BORSA is lates (Figur  2). Cluster 1 represented the ST1 
sequences and consisted of two closely related allelic profiles differing only in one target gene. 
Cluster 2 included the ST1660 isolates assigned to 12 distinct, but also closely related allelic profiles 
differing in 0 to 7 target genes only. The phylogenetic relationship of the two clusters was 
considerably distant, mirrored by the differences in 1697 of 1744 alleles included in the comparison. 
 
Figure 2. The minimum spanning tree showing the clonal relationship of 19 borderline oxacillin-
resistant S. aureus (BORSA) isolates based on a core genome multilocus sequence typing (cgMLST) 
analysis including 1744 genes using the SeqSphere+ software. Each circle represents an allelic profile 
Figure 2. The minimum spanning tree showing the clonal relationship of 19 borderline oxacillin-resistant
S. aureus (BORSA) isolates based on a core genome multilocus sequence typing (cgMLST) analysis
including 1744 genes using the SeqSphere+ software. Each circle represents an allelic profile and the
connecting lines display the number of different alleles between the distinct profiles. The individual
isolate IDs are shown within the circles, the collection date is given in brackets, while the sequence
types (ST) types are indicated by color: ST1 in light blue, ST1660 in red.
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2.3. Virulence Factors of the 19 Equine BORSA Isolates
The molecular characterization based on WGSs revealed that all isolates harbored genes encoding
the S. aureus bicomponent gamma-hemolysins (HlgA, HlgB and HlgC), alpha-hemolysin (Hla) and
delta-hemolysin (Hld). Moreover, all ST1 isolates were positive for a β-hemolysin (Hlb) converting
phage, which functionally inactivated the hlb gene (Table 1).
Table 1. Virulence genes of the 19 equine S. aureus isolates.
ST Isolate hlb fnbA fnbB ica sei selm seln selo φent2 selq seh lukD/E lukP/Q
ST1 IMT39129 - + + + - - - - - - + + +
ST1 IMT39173 - + + + - - - - - - + + +
ST1 IMT39701 - + + + - - - - - - + + +
ST1660 IMT39637 + + + + + + + + + + - + +
ST1660 IMT37083 + + + + + + + + + + - + +
ST1660 IMT37341 + - + + + + + + + + - + +
ST1660 IMT37410 + + + + + + + + + + - + +
ST1660 IMT37728 + + + + - + + + + + - + +
ST1660 IMT39233 + + + + + + + - + + - + +
ST1660 IMT39841 + - + + - + + + - + - + +
ST1660 IMT40768 + + + + + + + + + + - + +
ST1660 IMT40820 + + + + + + + + + + - + +
ST1660 IMT40952 + + + + + + + + + + - + +
ST1660 IMT41452 + + + + + + + + + + - + +
ST1660 IMT41468 + + + + - + + + + + - + +
ST1660 IMT43228 + + + + + + + + + + - + +
ST1660 IMT43231 + + + + + + + + + + - + +
ST1660 IMT43240 + + + + - + + + + + - + +
ST1660 IMT41899 + - - + - + + + + + - + +
+ = gene present, - = gene absent or deleted
All isolates harbored a similar set of genes associated with adherence, including ebpS (encoding
the elastin binding protein) and efb (encoding the extracellular fibrinogen binding protein). All isolates,
except isolates IMT37341, IMT39841 and IMT41899, were positive for the fibronectin binding protein
gene fnbA. Isolate IMT41899 was also negative for the gene fnbB. All isolates harbored the intercellular
adhesion gene cluster (ica), which is associated with biofilm formation.
The ST1660 isolates carried genes for staphylococcal enterotoxins (SE) and SE-like toxins associated
with the egc enterotoxin gene cluster, namely sei, selm, seln, and selo. Moreover, pseudogene φent2
was present in all but one [IMT39841] and selq was present among all ST1660 isolates, while the ST1
isolates harbored the enterotoxin gene seh. All isolates harbored the leukotoxin-encoding genes lukD
and lukE. All isolates were positive for the bacteriophage Saeq1 (acc. no. LT671578) harboring genes
(lukP and lukQ) which code for a further leukocidin (Table 1). For the staphylococcal complement
inhibitor (Scin)—also encoded on this phage—96% amino acid (aa) identity compared to the reference,
bacteriophage Saeq1, was observed. All isolates were negative for the genes encoding the toxic shock
syndrome toxin 1 (tst) and the Panton-Valentin leucocidin (PVL) genes lukF-PV and lukS-PV.
2.4. Antimicrobial Resistance Properties
Antimicrobial susceptibility testing was performed via broth micro- and macrodilution according
to the Clinical and Laboratory Standards Institute (CLSI) recommendations [38,39]. The MIC value
distribution and their classification into the categories susceptible, intermediate (if available) or resistant
is displayed in Table 2. Penicillin MIC values from 2 to ≥64 mg/L were determined for the 19 isolates
reported. Hence, all isolates were classified as resistant [38,39] and harbored the β-lactamase gene blaZ.
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Table 2. Distribution of minimal inhibitory concentrations (MIC) values of the 19 different equine S. aureus isolates.
No. of Isolates with MIC (mg/L) Susceptible Intermediate Resistant
Antimicrobial Agent(s) 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 no. % no. % no. %
Oxacillin - - - - 2 1 9 7 - - - 19 100 - - - -
Penicillin - - - - - - - 3 - - - - 16 - - - - 19 100
Ampicillin - - - - - 1 2 - - - - 1 15
Amoxicillin/clavulanic acid a - - - 3 - 9 7 - - - - - -
Imipenem 12 7 - - - - - - - - - - -
Ceftiofur - - - - 1 11 6 1 - - - - -
Cefquinome - - - - - 8 11 - - - - - -
Cefalothin - - 3 16 - - - - - - - - -
Cefotaxime - - - - - - - 11 8 - - - -
Cefoperazone - - - - - 3 8 8 - - - - -
Erythromycin - - - - 10 8 1 - - - - - - 18 94.7 1 5.3 - -
Tylosin tartrate 1 - - - 11 7 - - - - - - -
Tulathromycin - - - - - - 3 12 4 - -
Tilmicosin - - - - 12 7 - - - - - - -
Clindamycin - - 15 4 - - - - - - - - - 19 100 - - - -
Pirlimycin - - - - 13 6 - - - - - - -
Tiamulin - - - - 4 15 - - - - - - -
Ciprofloxacin - - - 9 6 1 2 1 - - - - 18 94.7 1 5.3 - -
Enrofloxacin - 1 4 10 1 2 1 - - - - - 15 78.9 1 5.3 3 15.8
Marbofloxacin - - - - 14 2 3 - - - - -
Nalidixic acid - - - - - - - 1 15 - 3 -
Gentamicin - - - - - - - - 7 11 1 - - - - - - 19 100
Kanamycin - - - - - - - 5 14
Streptomycin - - - - - 14 5 - - - - -
Neomycin - - 11 5 - - 2 1 - - -
Tetracycline - 16 - - - - - - 1 2 - - - 16 84.2 - - 3 15.8
Doxycycline - 10 6 - - - 1 2 - - - - - 10 52.6 6 31.6 3 15.8
Sulfamethoxazole/trimethoprima - - - 1 - 7 8 - 3 - - - - 16 84.2 - - 3 15.8
Florfenicol - - - - - 18 1 - - - - - -
Linezolid - - - - - 2 14 3 - - - - - 19 100 - - - -
Vancomycin - - - - - 8 11 - - - - - - 19 100 - - - -
Quinupristin/dalfopristin - - - - 10 9 - - - - - - - 19 100 - - - -
Grey shading indicates concentrations not included in the test panel. Isolates with growth throughout the panel have MIC values equal to or larger than the highest concentration
tested and are, therefore, displayed in the next higher concentration with grey shading; classification as susceptible, intermediate or resistant, according to CLSI [38,39] is indicated
by black vertical bars; species-specific clinical breakpoints for horses were applied for penicillin, enrofloxacin and doxycycline, the remaining breakpoints were adopted from human
medicine [38,39]. a amoxicillin and trimethoprim MIC values were used for the combinations amoxicillin/clavulanic acid (2:1) and sulfamethoxazole/trimethoprim (19:1), respectively.
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Broth microdilution revealed comparatively low oxacillin MICs of 0.25 or 0.5 mg/L for
the ST1 isolates, and, as expected, the WGSs lacked the methicillin resistance genes mecA,
mecB or mecC. Resistance to gentamicin and kanamycin, tetracyclines, and the combination
sulfamethoxazole/trimethoprim was observed. The respective aminoglycoside resistance genes
aacA-aphD and aadD, the tetracycline resistance gene tet(L) as well as the trimethoprim resistance gene
dfrG were detected in the WGSs. The enrofloxacin MICs of 0.5 or 1 mg/L classified the respective isolates
as resistant and the analysis of the quinolone resistance determining regions (QRDR) of GyrA/GyrB
and GrlA/GrlB [40,41] revealed that the isolates displayed the same aa alteration Ser80Tyr in GrlA
compared to a wildtype sequence (acc. no. D67075.1).
The ST1660 isolates had comparably higher MICs for oxacillin of 1 or 2 mg/L. Resistance to
gentamicin and kanamycin was found in all isolates, which corresponded well to the presence of
the aacA-aphD gene. The neomycin MIC values of 0.5 or 1 mg/L were lower than those obtained
for the ST1 isolates with MICs of 8 or 16 mg/L, which might be caused by the absence of the aadD
gene, which confers kanamycin/neomycin resistance. A single isolate was classified as intermediate to
erythromycin. In comparison to the ST1 isolates, the ST1660 isolates displayed lower enrofloxacin
MICs of 0.03 to 0.25 mg/L, resulting in the classification of one isolate as intermediate based on its
MIC of 0.25 mg/L. However, a single aa exchange Glu434Asp in GrlB was observed in the QRDRs.
Six isolates with doxycycline MICs of 0.25 mg/L were classified as intermediate.
The results of the quality control strain S. aureus ATCC® 29213 were always within the respective
QC ranges [38,39].
2.5. Investigation of the Reduced Susceptibility to Oxacillin
Agar disk diffusion for penicillin resulted in zone diameters of 8–18 mm, which classified the
isolates as resistant [38,39]. The ST1 isolates displayed remarkably larger zone diameters (16–18 mm)
than the ST1660 isolates (8–12 mm) (Table 3). A similar situation was observed for oxacillin, ampicillin,
ampicillin-sulbactam and amoxicillin-clavulanic acid, whereas the amoxicillin zone diameters were
comparable for the isolates of both STs and measured up to 8 mm (Table 3). Comparing the results
for ampicillin, and ampicillin-sulbactam as well as for amoxicillin and amoxicillin-clavulanic acid,
increased zone diameters (of≥5 mm) were detected for theβ-lactamase inhibitor containing compounds.
The results obtained with the quality control strains S. aureus ATCC® 25923 and Escherichia coli ATCC®
35218 were always within the respective QC ranges [38,39].
Table 3. Zone diameter values of the 19 S. aureus isolates.
ST a Isolate
Zone Diameter (mm) b,c
PEN (10 U) OXA (1 µg) AMP (10 µg) SAM (10/10 µg) AMX (20/10 µg) AMC (10 µg)
ST1 IMT39129 18 20 18 26 7 30
ST1 IMT39173 18 19 18 22 8 30
ST1 IMT39701 16 19 17 26 8 30
ST1660 IMT39637 10 8 9 18 no zone 22
ST1660 IMT37083 12 14 12 19 7 22
ST1660 IMT37341 10 12 10 16 no zone 20
ST1660 IMT37410 10 12 10 18 no zone 20
ST1660 IMT37728 10 12 10 18 no zone 20
ST1660 IMT39233 10 14 10 18 no zone 22
ST1660 IMT39841 8 14 10 16 no zone 20
ST1660 IMT40768 9 14 9 16 no zone 21
ST1660 IMT40820 10 14 10 17 no zone 20
ST1660 IMT40952 11 14 10 18 no zone 21
ST1660 IMT41452 9 14 10 18 no zone 20
ST1660 IMT41468 10 15 10 17 7 20
ST1660 IMT43228 10 14 11 18 no zone 21
ST1660 IMT43231 10 14 8 17 7 22
ST1660 IMT43240 12 15 12 20 7 24
ST1660 IMT41899 11 14 11 19 7 22
a ST = sequence type; b PEN = penicillin, OXA = oxacillin, AMP = ampicillin, SAM = ampicillin-sulbactam, AMX =
amoxicillin, AMC = amoxicillin-clavulanic acid c Bold numbers indicate resistance according to CLSI [38].
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Regarding the reduced susceptibility to oxacillin, the Fem (factors essential for methicillin
resistance) proteins [42] were further investigated, including the aa sequences of FemA, FemB, FemX,
FemC and FemD. Compared to the β-lactam susceptible S. aureus reference strain ATCC® 25923 (acc.
no. CP009361.1), the following situation was observed. Within the FemA protein sequence, all isolates
displayed the aa alteration Glu234Asp, while the ST1 isolates had an additional difference, Tyr195Phe.
Moreover, the ST1 isolates displayed the aa alteration Arg199Ser in the FemB sequence. Within the
FemX protein sequence, all isolates had an Asn18His alteration. While all ST1 isolates exhibited
only one additional aa exchange (Ile51Val), the ST1660 isolates showed two additional exchanges
(Asn155Thr and Thr262Lys) in the FemX protein sequence. There were no differences regarding the aa
sequences of FemC and FemD.
All isolates had aa differences in the catabolite control protein A (CcpA), a global transcriptional
regulator, shown to be associated with oxacillin resistance in staphylococci [43,44]. The following
differences were observed: Lys171Glu and Ser207Gly, and the ST1 isolates showed an additional
Ala197Glu exchange.
All ST1660 isolates had two aa differences (Ile456Val and Asp561Glu) in the phosphodiesterase
GdpP, for which is known, that mutations can lead to elevated oxacillin MICs [45,46]. The position
Ile456Val is located in the so-called desert hedgehog (DHH) domain [47,48].
Being the primary targets of β-lactam antibiotics, the penicillin binding proteins (PBPs) [42] were
also comparatively investigated. The PBP aa sequences of the analyzed isolates were compared to
the respective ones of the reference strain S. aureus ATCC® 25923 (acc. no. CP009361.1). Differences
could be detected in all investigated PBP aa sequences. All ST1 isolates showed two aa exchanges in
PBP1 (Asp118Asn, Val617Met), three in PBP3 (Gly167Arg, Lys504Arg, Asp563Glu) and one in PBP4
(Thr189Ser). The ST1660 isolates displayed a single variation in PBP2 (Val102Met), four differences in
PBP3 (Gly167Glu, Ala330Ser, Lys504Arg, Asp563Glu) and one in PBP4 (Glu398Ala). Moreover, all
isolates had an elongation of eleven aa at position 717 in the PBP2 aa sequence.
Furthermore, the aa sequences of the additional proteins that have been shown to be involved in
methicillin resistance, like the efflux pump regulator MgrA [49] and the multiple peptide resistance
factor MprF [50] involved in cell wall synthesis, showed no differences to the respective aa sequences
of S. aureus ATCC® 25923.
2.6. Overexpression and Induction of blaZ
The representative isolates (all three ST1 and ten ST1660) were subjected to β-lactamase activity
testing using a nitrocefin assay. The induction with ampicillin revealed a 5.05–19.10-fold increase of
β-lactamase production for the ST1660 isolates, while the ST1 isolates showed only a moderate increase
(3.17–3.40-fold) (Figure 3a). The Mann-Whitney-U-Test revealed a significant difference (U = 0.0;
p = 0.007) between the ST1 and the ST1660 isolates. Susceptibility testing after induction resulted, for
all but one isolate, in oxacillin MICs that were one to two dilution steps higher than the corresponding
values of the uninduced isolates (Figure 3b). The isolate IMT37083 (ST1660) showed no change in its
oxacillin MIC of 2 mg/L. For the remaining nine ST1660 isolates tested, oxacillin MICs increased to
4 mg/L, thus they were classified as resistant. Even though the ST1 isolates showed increased oxacillin
MICs of 1 mg/L, they were still classified as susceptible according to the CLSI standards [38,39].
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Figure 3. (a) Mean β-lactamase activity (nmol/min/µL) obtained by testing in duplicate and (b) oxacillin
MIC values of selected isolates before and after induction. Light grey = before induction, dark grey =
after induction.
The investigation of the β-lactamase operon containing genes encoding the proteins BlaZ, BlaR1
and BlaI revealed the differences between the sequence types. The aa sequences were compared to the
originally described sequence of S. aureus transposon Tn552 (acc. no. X52734.1) [51]. For the repressor
BlaI, only one aa alteration, Gly21Asp, was observed which was present in all ST1 isolates and the
ST1660 isolate IMT37083. The BlaZ proteins of the ST1 isolates had seven aa exchanges (Ser22Pro,
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Val86Ile, Glu145Gly, Tyr220Cys, Val9Ala, Ala112Glu and Pro217Ser). The aforementioned ST1660
isolate IMT37083 shared the latter three aa exchanges (Val9Ala, Ala112Glu and Pro217Ser) with the
three ST1 isolates and harbored the additional aa exchange Lys169Arg. In the BlaR1 sensor protein, all
ST1 isolates showed 32 aa exchanges, with 19 of them also occurring in the aforementioned ST1660
isolate IMT37083 (Figure 4). The remaining ST1660 isolates had four aa exchanges in BlaR1 (Ala91Thr,
Ser106Cys, Asp447Asn, and Phe491Leu).
Figure 4. Comparison of the aa sequences of BlaR1 of IMT41452, which represents the majority of the
ST1660 isolates, except the differing ST1660 isolate IMT37083, and IMT39129, which represents the ST1
isolates. The transposon Tn552 of S. aureus NCTC 9789 (acc. no. X52734.1) served as a reference. The
dots indicate the identity of aa, while letters indicate aa exchanges.
2.7. Susceptibility to Biocides
Comparative biocide susceptibility testing via broth macrodilution revealed MICs of 0.00006–0.0005%
for benzalkonium chloride (BAC), 0.125–0.5% for glutardialdehyde (GLU) and 0.00006–0.00025% for
chlorhexidine (CHX). The broth microdilution results were 0.000125–0.0005% (BAC), 0.25–0.5% (GLU) and
0.000125–0.00025% (CHX) (Table 4). Overall, the results vary between three to four dilution steps in broth
macrodilution and between two to three dilution steps in broth microdilution. The biocide MIC values
of the ST1 and ST1660 isolates did not show major differences. Only a slight difference could be seen
regarding the CHX MIC values. The S. aureus reference strain ATCC® 6538 was tested for comparative
reasons and showed comparable results to previous studies [37].
Table 4. MIC distribution obtained with broth micro- and macrodilution.
Method a and ST
BAC b (MIC in %) GLU (MIC in %) CHX (MIC in %)
0.00006 0.000125 0.00025 0.0005 0.125 0.25 0.5 0.00006 0.000125 0.00025
Micro ST1 3 1 2 3
Macro ST1 3 2 1 3
Micro ST1660 1 11 4 13 3 9 7
Macro ST1660 1 1 5 9 3 12 1 4 12
a Micro = broth microdilution, Macro = broth macrodilution b BAC = benzalkonium chloride, GLU =
glutardialdehyde, CHX = chlorhexidine. Numbers indicate the numbers of isolates showing the respective MIC.
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3. Discussion
Between 2015 and 2017, BORSA isolates caused infections in horses of a German equine clinic.
These isolates were initially noticed as they showed elevated MICs for oxacillin using VITEK2. However,
these MICs were classified as susceptible.
An analysis of whole genome sequencing (WGS) data revealed two lineages being associated with
the conspicuous oxacillin phenotypes, ST1-t127 and ST1660-t3043, -t2484 and -t549. ST1 is attributed to
CC1, which is known to be a livestock-associated putative pathogen, causing zoonotic infections [18].
The isolates with similar characteristics to our isolates (ST1-t127, ST1660-t549 and ST1660-t3043) have
been previously described as MRSA and MSSA in equine samples [6,11,21,25,26] and have also been
detected in samples obtained from humans in different European and non-European countries [28–33].
In addition, MSSA ST1660 with other spa types, t2484 for S. aureus from a horse in Germany [52] and
t3043 for an isolate obtained from a donkey in Tunisia [53] were described. The isolates attributed to
ST1-t127 belong to the three most prevalent lineages of MRSA in the Italian pig industry [54,55] and
were also detected in cattle in Italy and China, [56,57] and wild boars in Germany [58].
The two clusters obtained by cgMLST were in accordance with the multi locus sequence typing
(MLST) and could further differentiate the isolates. Interestingly, the four ST1660-t3043 isolates obtained
in 2015 cluster very closely together, showing 0-2 allelic differences only, while the isolates obtained in
other years were more distantly related (Figure 2). The correlation of the cgMLST and the spa types
revealed that the 14 isolates with spa type t3043 could be assigned into 11 allelic profiles by cgMLST.
However, it should be noted that one allelic profile was shared by two isolates with different spa
types, namely t549 and t3043. A former study on the relatedness of S. aureus outbreak isolates using
the SeqSphere+ cgMLST approach revealed that genomes with 0 to 8 allelic differences should be
considered as related, while those with 9 to 29 allelic differences seemed to be possibly related, and those
with 30 or more differences were rated as unrelated [59]. However, a lack of epidemiological metadata
concerning possible relatedness of individual cases forbids further speculation here. Moreover, a recent
study on equine MRSA obtained from horses directly at hospital admission revealed a very limited
number of genomic differences for unrelated equine ST398 MRSA as well [13].
All isolates were negative for PVL and the toxic shock syndrome toxin 1, a T-cell activating
superantigen (SAg). The ST1660 isolates carried further genes encoding SAgs, including enterotoxins
and enterotoxin-like proteins, which are beyond others associated with egc. However, only non-egc
encoded SAgs have been implicated in toxin-mediated diseases [60]. Thus, the role of egc-encoded
SAgs in equine S. aureus requires further investigation. At present, there is an ongoing discussion
about the impact of enterotoxins on colonization abilities of S. aureus. The ST1 isolates harbored the
enterotoxin gene seh, which is usually attributed to CC1 and the corresponding protein is known for
its binding affinity to human major histocompatibility complex class II [61]. The ST1 and ST1660
isolates were positive for the leukocidin genes lukP/Q located on a bacteriophage most similar to
Saeq1 (acc. no. LT671578) [62]. Very recently, this phage was reported for MRSA-ST398 isolated from
horses in the same area [13]. LukPQ preferentially kills equine neutrophils, but it also showed activity
towards human neutrophils at high concentrations [62]. Moreover, an important immune-modulating
factor, a variant of Scin, is also located on that phage. Previous research indicated a C3-inhibiting
activity of eqSCIN in plasma of a much broader range of hosts, including horses, humans, and pigs [63].
According to Monecke et al., most isolates of CC1 harbor a β-hemolysin converting phage, which is
supported by our findings [64].
Regarding the antimicrobial resistance properties, the ST1 isolates were resistant to penicillins,
aminoglycosides, enrofloxacin, sulfamethoxazole/trimethoprim and tetracyclines and accordingly
classified as multiresistant, based on their resistance to three or more classes of antimicrobial agents [65].
Similar resistance profiles were also detected among BORSA isolates of ST1 and ST1660 and MRSA
CC398 from horses in equine clinics [13,21]. The ST1660 isolates were resistant to penicillins, and
aminoglycosides. It should be mentioned, that except for penicillin, enrofloxacin and doxycycline, no
equine-specific clinical breakpoints for the tested antimicrobial agents were available [38].
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Regarding the reduced oxacillin susceptibility, the VITEK2 results were compared with the broth
microdilution results. The broth microdilution results were generally lower than the results obtained by
VITEK2. Moreover, higher MICs were determined for the ST1660 isolates compared to the ST1 isolates.
All isolates lacked the known mec genes, encoding an additional PBP and causing resistance
to virtually all β-lactams, except specific anti-MRSA compounds [38]. Moreover, no gene with
considerable homology to mec genes could be detected in the wholegenome sequences so far. Therefore,
other potential causes were analyzed. An analysis of the PBPs, compared to the susceptible S. aureus
ATCC® 25923 (acc. no. CP009361.1) revealed aa alterations in PBP1, PBP2, PBP3 and PBP4, even
though none of these differences were within the functional transglycosylase or transpeptidase
domains [1,2,66–68]. Since Morroni et al. compared the PBPs of ceftobiprole-resistant MRSA isolates
with the vancomycin-resistant mecA-carrying MRSA Mu50 [69], a comparison of our isolates with Mu50
(acc. no. NC_002758.2) was performed. Some of the mutations present in Mu50 compared to S. aureus
ATCC® 25923, were also present in our collection, including the eleven aa terminal elongation in PBP2,
but also the aa differences Gly167Arg, Lys504Arg and Asp563Glu in PBP3, as well as Thr189Ser (ST1)
in PBP4. Since Mu50 is an MRSA isolate with an alternative PBP2a, it cannot be stated whether these
aa changes are involved in the generation of elevated oxacillin MICs.
The mutations in the gdpP gene, which encodes a phosphodiesterase that regulates gene expression,
have also been described in association with borderline oxacillin resistance [45]. The GdpP protein
has two functional domains, GGDEF and DHH. The GGDEF domain contains a diguanylate cyclase,
conferring the capacity to synthesize the second nucleotide messenger cyclic di-GMP, and the DHH
domain contains the phosphodiesterase characteristic catalytic DHH motif, mediating hydrolysis of
cyclic di-AMP, which is, besides others, involved in cell wall homeostasis [47,48]. Only one aa difference
of the ST1660 isolates (Ile456Val) is located in the DHH domain. The fact that one aa alteration is located
in a functional domain might indicate a possible contribution to the reduced oxacillin susceptibility of
the ST1660 isolates. These alterations were only present among the ST1660 isolates and, therefore, did
not explain the BORSA phenotype of the ST1 isolates. However, the comparatively lower oxacillin
MICs confirmed for the ST1 isolates versus the ST1660 isolates could possibly be in accordance with
this finding. A study by Griffiths and O’Neil revealed that neither a mutation Asp418Ala within the
DHH domain nor a truncation of GdpP to 370 aa, causing a deletion of this domain, contributed
to oxacillin resistance [45]. Therefore, the aa changes in the GdpP protein reported here for ST1660
isolates might have little or no effect on the phenomenon of elevated oxacillin MICs in this study.
In the case of MRSA, some genes, e.g., those of the fem family, are important for methicillin
resistance [70]. However, the respective Fem proteins were found in the WGSs of susceptible and
resistant S. aureus isolates. In MRSA, the inactivation of these factors results in a Fem-specific reduced
resistance to oxacillin in the corresponding strains, ranging from slightly decreased MICs to complete
hypersusceptibility toβ-lactam antibiotics [42,71]. Thus far, studies only showed a reduction of oxacillin
resistance in usually resistant MRSA isolates, when these factors were altered or deleted [42,70,72].
Consequently, the involvement of the Fem alterations in the increase of oxacillin MICs is not likely.
In line with this, the deletion or inactivation of the carbon catabolite protein CcpA was only shown
to increase the β-lactam susceptibility in S. aureus, including MRSA, Staphylococcus epidermidis as well
as different streptococci [43,44,73,74]. Therefore, the detected aa differences did not seem to play a role
in the reduced oxacillin susceptibility.
Among staphylococci, the resistance to penicillins is commonly mediated by the blaZ gene.
This is in accordance with this study, since all isolates were classified as penicillin-resistant by broth
microdilution and agar disk diffusion and carried the blaZ gene. As expected, the β-lactam compounds
containing a β-lactamase inhibitor revealed larger zone diameters than the respective β-lactam
compound alone. All isolates showed zone diameter differences of ≥5 mm for the combinations with
a β-lactamase inhibitor, indicating the presence of an active β-lactamase. This is in accordance with
the results from previous studies. Maalej and colleagues revealed the differences of at least 5 mm for
oxacillin zone diameters with and without clavulanic acid [75].
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Borderline oxacillin resistance can be caused by the overexpression of the β-lactamase gene
blaZ [16]. β-Lactamase hyperproduction was evaluated as an underlying mechanism, since oxacillin
is usually no target for β-lactamases. Using a nitrocefin assay for the selected isolates, inducible
β-lactamase production was detected in all 13 isolates tested. Interestingly, the ST1660 isolates showed
a higher degree of induction, which might explain the higher oxacillin MICs (Figure 3). Subsequent
susceptibility testing after induction with ampicillin, revealed that all isolates but one showed higher
oxacillin MICs than without induction. While all ST1 isolates were still classified as susceptible, nine of
ten tested ST1660 isolates reached oxacillin MICs of 4 mg/L and were classified as resistant. While
all other ST1660 isolates displayed almost no differences to the originally described BlaZ-BlaR1-BlaI
proteins of transposon Tn552 of S. aureus strain NCTC 9789 (acc. no. X52734.1), ST1660 isolate
IMT37083 shared 19 of the 32 aa differences within the respective proteins with the ST1 isolates. Since
BlaR1 is the sensor protein for extracellular β-lactam antibiotics [51,76–78], it is possible, that these
aa changes result in a comparatively lower expression of blaZ in ST1 isolates and IMT37083 in the
presence of β-lactam antibiotics. The observed increase of the oxacillin MICs after induction of all
but one isolate (IMT37083) tested points towards borderline oxacillin resistance due to β-lactamase
hyperproduction [16,75].
Biocide susceptibility testing was performed for BAC, GLU, and CHX using broth macro- and
microdilution as an additional characterization of the isolates [37,79]. In the equine clinic, only BAC is
used, as a compound of a floor disinfectant (7.6 g BAC per 100 g disinfectant). The MICs for GLU
and CHX of the isolates in this study were below the standard concentrations used and did not differ
remarkably from the MICs of the S. aureus reference strain ATCC® 6538. BAC is often used as an
additive and not as a single antibacterial agent. Regarding BAC, the highest MIC of the isolates
corresponds to the lowest used concentration of this agent.
In conclusion, in a two-year period, two closely related lineages of S. aureus, causing infections in
an equine clinic, were identified. These isolates were attributed to sequence types/clonal complexes
(including MRSA) that are commonly isolated from equine samples, but have also a zoonotic
potential [21–26]. Here, borderline oxacillin resistance seems to be associated with the hyperproduction
of the β-lactamase BlaZ. The detection and correct classification of isolates expressing the BORSA
phenotype is of major importance since the effectiveness of β-lactams is limited and therapy failure
might occur when these isolates cause infections.
4. Materials and Methods
4.1. Background Information and Bacterial Isolates
During the years 2015-2017, routine diagnostics identified 19 S. aureus isolates with elevated MICs
for oxacillin via VITEK2. These isolates originated from 17 equine patients of a veterinary clinic (Table 5).
One sample was from an injured horse and one from respiratory disease. All other samples were from
surgical site infections. Most of the cases (eleven samples from nine patients) were from orthopedic
procedures. Four samples were from colic patients and two from surgeries of the genito-urinary tract.
All surgical patients were treated with a combination of amoxicillin and gentamicin, either as single
shot therapy before surgery or up to six days after surgery. The injured patient and four with surgical
site infections were additionally treated with the combination of sulfamethoxazole/trimethoprim from
three up to 13 days. One of these patients had to undergo a second surgery where a single shot dose of
amikacin was injected.
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Table 5. Background data for the S. aureus isolates.
Isolate Date History Surgery Sample Material Age Sex
IMT39129 a 9 April 2016 arthritis yes synovial fluid 5 years gelding
IMT39173 a 11 April 2016 arthritis yes tissue sample 5 years gelding
IMT39701 12 July 2016 fracture yes wound sample <1 year stallion
IMT39637 22 June 2016 trauma no wound sample n.k. gelding
IMT37083 13 July 2015 fracture yes wound sample 14 years mare
IMT37341 24 August 2015 colic surgery yes abscess 8 years stallion
IMT37410 11 September 2015 castration yes wound sample 1 year gelding
IMT37728 5 October 2015 colic surgery yes wound sample 11 years gelding
IMT39233 25 April 2016 rupture of the urinarybladder yes wound sample 2.5 weeks stallion
IMT39841 11 August 2016 wound healing disorder yes wound sample 14 years gelding
IMT40768 7 December 2016 fracture yes wound sample 4 years mare
IMT40820 28 December 2016 colic surgery yes wound sample 1 year mare
IMT40952 17 January 2017 colic surgery yes TBS 8 years gelding
IMT41452 27 January 2017 wound healing disorder yes wound sample 15 years gelding
IMT41468 2 February 2017 sinusitis yes wound sample 5 years gelding
IMT43228 b 16 June 2017 fracture yes wound sample 7 years mare
IMT43231 b 19 June 2017 fracture yes wound sample 7 years mare
IMT43240 22 June 2017 colic surgery yes wound sample 6 years gelding
IMT41899 15 February 2017 fracture yes wound sample 14 years mare
Isolates originating from the same patients are indicated with the same superscript letters. TBS = tracheobronchial
secretion, n.k. = not known.
4.2. Characterization of the Isolates
The DNA extraction for WGS was performed using the QIAamp® DNA Mini Kit (QIAGEN,
Hilden, Germany) with some adaptations for staphylococci. Before starting the official protocol, the
cells were mixed with 25 µL lysostaphin solution (0.1 mg/mL) and incubated for 25 min at 37 ◦C.
Then, 75 µL TE buffer and 25 µL proteinase K (0.1 mg/L) were added and the cells were incubated
for 25 min at 37 ◦C. Then, 75 µL PBS and 2 µL RNAse A (2 µg/µL) were added and slightly mixed.
After this, the protocol for the kit was followed starting with the addition of AL buffer. The libraries
for WGS were prepared using the Nextera XT library preparation kit (Illumina Inc., San Diego,
CA, USA) according to the manufacturer’s instructions. The 2 × 300 bp paired-end sequencing in
30-fold multiplexes was performed on the Illumina MiSeq platform. The genome sequences were
de novo assembled using Newbler (Roche, Basel, Switzerland) and SPAdes v3.12.0 [80]. The nucleotide
sequences were analyzed with Geneious v11.1.4 (Biomatters Ltd., Auckland, NewZealand) and
annotated with the subsystem technology server (RAST) [81] and Prokka [82] which were compared
with BLAST (National Center for Biotechnology Information, Rockville Pike, USA) [83] results. Further
investigations were performed by using ResFinder [84] of the Center for Genomic Epidemiology
(http://www.genomicepidemiology.org/). The virulence factors were identified by using VFanalyzer of
VFDB (http://www.mgc.ac.cn/cgi-bin/VFs/v5/main.cgi?func=VFanalyzer) and checked using Geneious
v11.1.4. The associated mobile genetic elements including pathogenicity islands and phages were
determined using Geneious v11.1.4 software. The STs were derived from the pubmlst database (https:
//pubmlst.org) and spa types were deduced using the Ridom Spa Server (http://www.spa.ridom.de).
Whole genome sequences were analyzed for the proteins known to play a role in oxacillin resistance:
GdpP, FemA, FemB, FemC (GlnR), FemD (GlmM), MgrA, CcpA and MprF as well as the penicillin
binding proteins (PBP) 1, 2, 3 and 4. The sequences of these proteins were compared with S. aureus
ATCC® 25923, an oxacillin-susceptible reference strain (acc. no. CP009361.1). The blaZ-blaI-blaR1
operon was compared to the respective region of the originally described transposon Tn552 (acc. no.
X52734.1) [51]. The analyses were carried out with Geneious v11.1.4.
4.3. Phylogenetic Analysis
The molecular epidemiology was investigated using the previously generated WGSs as FASTA
files for the S. aureus core genome multilocus sequence typing (cgMLST) approach. For this, the
software SeqSphere+ version 6.0.2 (Ridom GmbH, Münster, Germany) was used [85,86]. To illustrate
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the clonal relationship between the different isolates, a minimum-spanning tree was built based on a
distance matrix of the core genome allelic profiles including 1744 of 1861 possible target genes, using
the “pairwise ignoring missing values” option of the software.
4.4. Antimicrobial Susceptibility Testing
The routine diagnostics performed antimicrobial susceptibility testing via VITEK2 according
to the manufacturer’s instructions. Additional susceptibility testing to 31 antimicrobial agents was
performed by broth microdilution according to the CLSI recommendations [38,39] using sensititreTM
microtiter plates. S. aureus ATCC® 29213 was used for quality control. The antimicrobial susceptibility
testing by broth microdilution was repeated for the β-lactam antibiotics using selected isolates (all three
ST1 and ten ST1660 isolates), after the induction with ampicillin [0.25 µg/mL (ST1) or 32 µg/mL (ST1660)
ampicillin (Roth®, Karlsruhe, Germany)], to investigate the effects of induced β-lactamase production.
The inoculum for the induction testing was prepared using the growth method, where the isolates
were incubated with the respective amount of ampicillin for 4 h in cation-adjusted Mueller-Hinton
broth (CAMHB) and then, the bacterial suspension was adjusted to McFarland 0.5. Additionally, the
susceptibility to kanamycin (Roth®, Karlsruhe, Germany) was tested via broth macrodilution [38,39].
4.5. Investigation of β-Lactamase-Production
Agar disk diffusion [39] was performed using BBL™ Sensi Discs for penicillin (10 IU), oxacillin
(1 µg), ampicillin (10 µg) and amoxicillin/clavulanic acid (20/10 µg) and Oxoid™ discs for amoxicillin
(10 µg) and ampicillin/sulbactam (10/10 µg) on Mueller-Hinton agar (MHA) plates. S. aureus ATCC®
25923 and E. coli ATCC® 35218 were used for quality control purposes, according to CLSI standard [39].
The results of agar disk diffusion for β-lactam antibiotics with and without a β-lactamase inhibitor
were comparably investigated.
Using a nitrocefin-basedβ-Lactamase Activity Assay Kit (Sigma-Aldrich®, Munich, Germany), the
β-lactamase activity of all ST1 isolates (n = 3) and selected ST1660 isolates (n = 10) were quantitatively
investigated. Therefore, the isolates were cultured overnight in brain-heart-infusion (BHI, Oxoid,
Wesel, Germany) at 37 ◦C. The next day, 5 mL BHI with and without 0.25 µg/mL (ST1) or 32 µg/mL
(ST1660) ampicillin (Roth®, Karlsruhe, Germany) were inoculated with 200 µL of the overnight cultures
and incubated for 4 h at 37 ◦C. Following the manufacturer’s instructions, the reaction was prepared in
duplicate with a sample volume of 20 µL per isolate and the absorbance was measured at a wavelength
of 490 nm, every 60 s for one hour. The standard curves were evaluated for every microtiter plate and
β-lactamase activity was calculated, according to the manufacturer’s instructions.
4.6. Biocide Susceptibility Testing
Comparative biocide susceptibility testing was performed using a broth macrodilution method [37]
and a broth microdilution method, which has been developed in this research group [79]. S. aureus
ATCC® 6538 was tested for comparative reasons and the results were compared to those of a previous
interlaboratory trial [37]. The optical densities were adjusted according to German Veterinary Medical
Society (DVG) standards for biocide efficacy testing [87]. For broth microdilution, twofold dilution
series were prepared in 100 µL per well on a 96 well plate. The biocide solutions were prepared in
deionized water and the inoculum was prepared in tryptic soy broth (TSB). The inoculum was added to
a final testing volume of 200 µL and the results were read after incubation for 24 h at 37 ◦C. The MIC was
defined as the first well concentration without visible growth. The tested biocides were BAC (Roth®,
Karlsruhe, Germany), GLU (Roth®, Karlsruhe, Germany) and CHX (Sigma®, Munich, Germany).
The test ranges were prepared in twofold dilution series; 0.000008–0.004% for BAC, 0.008–4% for GLU
and 0.00001–0.0005% for CHX.
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4.7. Statistical Analysis
The statistical analysis was performed using IBM®SPSS® Statistics Version 25. To compare the
β-lactamase inducibility of the isolates, non-parametric Mann-Whitney-U-test was performed.
4.8. WGS Submitted to GenBank
This Whole Genome Shotgun project has been deposited at GenBank under the accession numbers
VSYP00000000 (IMT41899), VSYQ00000000 (IMT43240), VSYR00000000 (IMT43231), VSYS00000000
(IMT43228), VSYT00000000 (IMT41468), VSYU00000000 (IMT41452), VSYV00000000 (IMT40952),
VSYW00000000 (IMT40820), VSYX00000000 (IMT40768), VSYY00000000 (IMT39841), VSYZ00000000
(IMT39233), VSZA00000000 (IMT37728) VSZB00000000 (IMT37410), VSZC00000000 (IMT37341),
VSZD00000000 (IMT37083), VSZE00000000 (IMT39637), VSZF00000000 (IMT39701), VSZG00000000
(IMT39173) and VSZH00000000 (IMT39129).
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